FDA to weigh easing limits on unproven peptides promoted by RFK Jr. Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026: What It Means for Providers FDA's Overreach on Compounded Peptides